Neos Therapeutics buy, $15 target, reiterated at BMO
BMO Capital analyst Gary Nachman reiterates Outperform rating and $15 price target on Neos Therapeutics (NASDAQ: NEOS), noting Adzenys XR-ODY continues to show strong and steady growth, as the company reports earnings on March 14th.
Nachman comments, ” Adzenys XR-ODT Rxs jumped 9% to 2,760 for the week ending 3/3, according to IMS. We are pleased to see the sustained growth streak since the EOY holiday season. We continue to believe the strong execution behind Adzenys, as well as the two pipeline products (PDUFA dates later this year) are underappreciated. The stock has rallied a bit recently off the bottom, but we still see a lot more room to run; reiterate our Outperform.”